In summary, we provide evidence of naturally occurring catalytic loss-of-function TYK2 variants and reduced expression of TYK2 in B-ALL patients and propose that both mechanisms could contribute to facilitate tumour expansion. The gene discussed is TYK2; the disease is neoplasm.